Religious debate [Regulatives / Guidelines]

posted by nobody – 2016-02-14 16:23 (2983 d 20:50 ago) – Posting: # 15990
Views: 16,043

Hi Danmark :-D

❝ PK in drug development is all about impressing the assessor with complex models having a million effect estimates of dubious value. It is not about making sense. Just sayin'...


I heard in the past that each and every piece of modeling (wherever submitted in the EU when any kind of non-national marketing authorization is applied for) is going for review to Sweden.

I would not build any relevant argumentation on models clearly identifiable as nonsense in this situation, huh? ;-)

Kindest regards, nobody

Complete thread:

UA Flag
Activity
 Admin contact
22,984 posts in 4,822 threads, 1,650 registered users;
43 visitors (0 registered, 43 guests [including 5 identified bots]).
Forum time: 14:13 CEST (Europe/Vienna)

You can’t fix by analysis
what you bungled by design.    Richard J. Light, Judith D. Singer, John B. Willett

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5